Institut National de la Santé et de la Recherche Médicale, Centre de Recherche desCordeliers, Sorbonne Université, Université de Paris, Paris, France.
LiteVax B.V., Oss, Netherlands.
Front Immunol. 2023 Jan 9;13:1086752. doi: 10.3389/fimmu.2022.1086752. eCollection 2022.
We retrospectively analyzed the immunopotentiating mechanism of an oil-in-water (O/W) emulsion-based vaccine adjuvant LiteVax™ Adjuvant (LVA) that contains CMS (Maltose 4'-monosulphate 1,2,3,6,2',3',6'-heptadecanoic acid ester), squalane, Tween 80 in phosphate buffered saline. Despite being effective in animal models, the immunological mechanisms by which LVA exerts adjuvant function are not known. As dendritic cells (DC) are key for initiating and propagating the immune response, we have investigated the effect of LVA and of its components on the DC function. We show that CMS but not LVA significantly enhances the expression of DC activation-associated markers, cytokine secretion, and CD4 T cell responses. On the other hand, CMS ZERO [non-sulphated sucrose fatty acid esters (ZERO)], used as a control, had no such activity. Our data identified the unique nature of CMS in LVA, and propose that LVA acts as a delivery system, and CMS acts as an immunostimulatory agent.
我们回顾性分析了油包水（O/W）乳液型疫苗佐剂 LiteVaxTM 佐剂（LVA）的免疫增强机制，该佐剂含有 CMS（麦芽糖 4'-单硫酸盐 1,2,3,6,2',3',6'-十七烷酸酯）、角鲨烷、吐温 80 在磷酸盐缓冲盐水中。尽管在动物模型中有效，但 LVA 发挥佐剂作用的免疫机制尚不清楚。由于树突状细胞（DC）是启动和传播免疫反应的关键，我们研究了 LVA 及其成分对 DC 功能的影响。我们表明，CMS 而不是 LVA 可显著增强 DC 激活相关标志物、细胞因子分泌和 CD4 T 细胞反应的表达。另一方面，作为对照的 CMS ZERO[无硫酸盐蔗糖脂肪酸酯（ZERO）]则没有这种活性。我们的数据确定了 LVA 中 CMS 的独特性质，并提出 LVA 作为一种递送系统，而 CMS 作为一种免疫刺激剂。
